New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based peptide vaccines

Melanoma Research

Volumn 6, Issue 1, 1996, Pages 11-24

  Maeurer, M J ^a   Storkus, W J ^a   Kirkwood, J M ^a   Lotze, M T ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Biomedical Science Tower W1540 ^*  (United States)

Author keywords

Melanoma; Peptide vaccine; T cell epitope; Treatment

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; EPITOPES; HUMANS; IMMUNOTHERAPY, ACTIVE; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OLIGOPEPTIDES; T-LYMPHOCYTES;

EID: 0030043549     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199602000-00003     Document Type: Review

References (102)

1. Vose BM, Moore M. Tumor-infiltrating lymphocytes: a marker of host response. Semin Haematol 1985; 22: 27-46.
2. Topalian S, Solomon D, Rosenberg SA. Tumour-specific lysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714-3720.
3. Townsend ARM, Rothbard J, Gotch FM, et al. The epitopes of influenzea nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44: 959-967.
4. De Bruijn MHL, Nieland JD, Schumacher TNM, et al. Mechanisms of induction of primary virus-specific cytotoxic T cell responses. Eur J Immunol 1992; 22: 3013-3018.
5. Sanderson F, Kleijmeer MJ, Kelly A, et al. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science 1994; 266: 1566-1569.
6. Karlsson L, Peleraux A, Lindstedt R, et al. Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells. Science 1994; 266: 1569-1573.
7. Braciale TJ, Braciale VI. Antigen presentation: structural themes and functional variations. Immunol Today 1991, 12: 14-18.
8. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-1327.
9. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
10. Lotze MT, Chang AE, Seipp CA, et al. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment related morbidity and histologic findings. JAMA 1986; 256: 3117-3124.
11. Rosenberg SA, Packard B, Aebersold PM, et al. Immunotherapy of patients with metastatic melanoma using tumor infiltrating lymphocytes and interleukin-2. N Engl J Med 1988; 319: 1676-1680.
12. Robbins PF, El-Gamil M, Kawakami Y, et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994; 54: 3124-3126.
13. Townsend ARM. Antigen recognition by class I-restricted T-lymphocytes. Annu Rev Immunol 1989; 7: 601-607.
14. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993; 177: 265-272.
15. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154: 2257-2265.
16. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987; 28: 267-270.
17. Linsley PS, Green JL, Tan P, et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176: 1595-1604.
18. Hathcock KS, Laszlo G, Dickler HB, et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 1993; 262: 905-907.
19. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-569.
20. Shahinian A, Pfeffer K, Lee KP, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261: 609-612.
21. Ronchese F, Hausmann B Hubele S, et al. Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo. J Exp Med 1994; 179: 809-817.
22. Walunas TL, Lenschow DJ, Bakker CY, et al. A-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413.
23. Milich DR, Linsley PS, Hughes JL, et al. Soluble CTLA-4 can suppress autoantibody production and elicit long term unresponsiveness in a novel transgenic model. J Immunol 1994; 153: 429-435.
24. Hathcock KS, Laszlo G, Pucillo C, et al. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function J Exp Med 1994; 180: 631-640.
25. Larsen CP, Ritchie SC, Hendrix R, et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 1994; 152: 5208-5219.
26. Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) hind with similar avidities hut distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1: 793-801.
27. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/ Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707-718.
28. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonohese diabetic mouse. J Exp Med 1995; 181: 1145-1155.
29. Hellstrom KE, Hellstrom I, Linsley P, et al. On the role of constimulation in tumor immunity. Ann N Y Acad Sci 1993; 690: 225-230.
30. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993; 14: 483-486.
31. Brown MG, Driscoll J, Monaco JJ. MHC-linked low-molecular mass polypeptide subunits define distinct subsets of proteasomes. Implications for divergent function among distinct proteasome subsets. J Immunol 1993; 151: 1193-1197.
32. Monaco JJ. A molecular model of MHC class I-restricted antigen processing. Immunol Today 1992; 13: 173-177.
33. Joyce S, Nathenson SG. Methods to study peptides associated with MHC class I molecules. Curr Opinion Immunol 1994; 6: 24-28.
34. Falk K, Rotzschke O, Stevanovic J et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 290-294.
35. Falk K, Rotzschke O. Consensus motifs and peptide ligands of MHC class I molecules. Semin Immunol 1993; 5: 81-87.
36. Kawakami Y, Eliyahu S, Delgade CH, et al. Identification of melanoma antigens recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458-6462.
37. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1047.
38. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T-lymphocytes directed against tumour antigen MZ2-E. J Exp Med 1992; 176: 1453-1458.
39. Van der Bruggen P, Szikora J-P, Boel P, et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw* 16018. Eur J Immunol 1994; 24: 2134-2140.
40. Zakut R, Topalian ASL, Kawakami Y, et al. Differential expression of MAGE-1, -2, -3 messenger RNA in transformed and normal cell lines. Cancer Res 1993; 53; 54-57.
41. Shamamian P, Mancini M, Kawakami Y, et al. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest. Cancer Immunol Immunother 1994; 39: 73-79.
42. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921-930.
43. Van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 24: 3038-3043.
44. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2: 167-175.
45. Boon T, Gajewski TF, Couli PG. From defined human tumor antigens to effective immunization. Immunol Today 1995; 16: 334-336.
46. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 489-495.
47. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994; 24: 759-764.
48. Wang R-F, Robbins PF, Kawakami Y, et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995; 181: 799-804.
49. Wang R-F, Robbins PF, Kawakami Y, et al. A novel human cancer antigen resulting from translation of an alternative open reading frame of TRP-1. JEM, submitted.
50. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumour. Proc Natl Acad Sci USA 1994; 91: 3515-3519.
51. Coulie PG, Brichard V, VanPel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180 35-42.
52. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally-processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995; 181: 363-368.
53. Bakker ABH, Schreurs MWJ, de Boer AJ, et al. Melanocyte lineage-specific gp100 is recognized by melanoma derived tumor infiltrating lymphocytes. J Exp Med 1994; 179: 1005-1009.
54. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716-719.
55. Robbins PF, El-Gamil M, Li YF, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24 restricted tumor-infiltrating lymphocytes. J Immunol 1995; 154: 5944-5950.
56. Robbins PF, Rosenberg SA. Antigens recognized by HLA-A24 restricted tumor infiltrating. 1995. 9th International Congress of Immunology, San Francisco, CA, USA, 23-29 July 1995. Abstract book, A 3924, p. 661; and personal communication.
57. Aberle H, Butz S, Stappert J. et al. Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J Cell Sci 1994; 107: 3655-3663.
58. Nathke IS, Hinck L, Swedlow JR, et al. Defining interactions and distributions of cadherin and catenin complexes in polarized epithelial cells. J Cell Biol 1994; 125: 1341-1352.
59. Sommers CL, Gelmann EP, Kemler R, et al. Alterations in beta-catenin phosphorylation and plakoglobin expression in human breast cancer cells. Cancer Res 1994; 54: 3544-3552.
60. Kawanishi J, Kato J, Sasaki K, et al. Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol 1995; 15 1175-1181.
61. INK4a-insensive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1995; 1281-1284.
62. Kraus C, Liehr T, Hulsken J, et al. Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development. Genomics 1994; 23: 272-274.
63. Munemitzu S, Albert I, Souza B, et al. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995; 92: 3046-3050.
64. Kanai Y, Ochiai A, Shibata T, et al. c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun 1995; 208: 1067-1072.
65. Shiozaki H, Kadowaki T, Doki Y, et al. Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br J Cancer 1995; 71: 250-258.
66. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991; 252: 1308-1310.
67. Sette A, Alexander J, Ruppert J, et al. Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu Rev Immunol 1994; 12: 413-431.
68. Jameson SC, Bevan MJ. T cell receptor antagonists and partial agonists. Immunity 1995; 2: 1-11.
69. Bertoletti A, Sette A, Chisari FV, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369: 407-410.
70. Klenerman P, Rowland-Jones S, McAdam S, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants. Science 1994; 369: 403-407.
71. Kageshita, T, Wang Z, Calorini L, et al. Selective loss of human leucocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leucocyte antigen. Cancer Res 1993; 53: 3349-3354.
72. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus downregulation in melanoma cell lines. J Immunol 1994; 153: 1225-1237.
73. D'Urso C, Wang Z, Cao Y, et al. Lack of HLA class I antigen expression by cultured melanoma cell FO-1 is due to a defect in β2-microglobulin expression. J Clin Invest 1991; 87: 284-289.
74. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing J Exp Med 1993; 177: 265-272.
75. Cromme FV, Airey J, Heemels M-T et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179: 335-340.
76. Maeurer MJ, Gollin S, Martin DM, et al. Escape from immune recognition: Lethal recurrence in a patient characterized by downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. Lancet, submitted.
77. Hoon DS, Yuzuki D, Hayashida M, et al. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 1995; 154: 730-737.
78. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-482.
79. Livingston PO, Natoli EJ, Calves MJ, et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987; 84: 2911-2116
80. Degiovanni G, Lahaye T, Herin M, et al. Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones. Eur J Immunol 1988; 18 671-676.
81. Maeurer MJ, Hurd S, Martin DM, et al. Cytolytic T-cell clones defined HLA-A2 restricted human cutaneous melanoma peptide epitopes - correlation with T-cell receptor usage. Cancer J 1995; 1: 162-170.
82. Maeurer MJ, Martin DM, Storkus WJ, et al. Evidence for shared TCR usage in CTL recognizing HLA-A2 presented antigens shared by melanoma and melanocytes. Immunol Today, in press.
83. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor Z chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613-5616
84. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer 1993; 53: 5610-5612.
85. Guilloux Y, Viret C, Gervois N, et al. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol 1994; 24: 1966-1973.
86. Piali I, Fichtel A, Terpe H-J, et al. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995; 181: 811-816.
87. Valitutti S, Müller S, Culls M, et al. Serial triggering of many T-cell receptors by a few serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 1995; 375: 104.
88. Blay J-Y, Negrier S, Combaret V, et al. Serum level of interleukin-6 as a prognosistic factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-3322.
89. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model predicting ten year survival in patients with primary melanoma based on readily available clinical and histologic attributes. Submitted for publication.
90. Frank SJ, Rellmann R, Applewhite J, et al. Predictors of long-term survival in stage IV melanoma. In: Proceedings of the American Society of Clinical Oncologists, Annual Meeting, 1995; 14: 411(1302).
91. Royal RE, Steinberg SM, White DE, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Submitted for publication.
92. Lotze MT, Rubin JT. Interleukin-2. In Le Roith D, Bondy C, eds. Growth Factors and Cytokines in Health and Disease Greenwich, CT: JAI Press, Inc; 1996, in press.
93. Ott G, Barchfeld GL, Chernoff R, et al. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. Submitted for publication.
94. Salgaller ML, Weber JS, Koenig S, et al. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother 1994; 39: 105-116.
95. Inaba K, Inaba M, Naito M, et al. Dendritic cell progenitors phagocytose particulates, including Bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med 1993; 178: 479-485.
96. Sallustro F, Lanzaveccia a. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-1115.
97. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognize a shared melanoma associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994; 91: 9461-9465.
98. Aichele P, Brduscha-Riem K, Zinkernagel RM, et al. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 1995; 182: 261-266.
99. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991; 353: 858-851.
100. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 1990; 63: 1249-1256.
101. Moskophidis D, Lechner f, Pircher HP, et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362: 758-761.
102. Nowak MA, May RM, Phillips RE, et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995; 375: 606-611.